Compugen Ltd. (USA)  

(Public, NASDAQ:CGEN)   Watch this stock  
Find more results for CGEN
8.36
-0.25 (-2.90%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.31 - 8.70
52 week 6.27 - 12.43
Open 8.69
Vol / Avg. 86,783.00/142,513.00
Mkt cap 438.26M
P/E     -
Div/yield     -
EPS -0.23
Shares 48.47M
Beta 1.15
Inst. own 13%
May 18, 2015
Q1 2015 Compugen Ltd Earnings Release (Estimated) Add to calendar
Feb 10, 2015
Q4 2014 Compugen Ltd Earnings Call
Feb 10, 2015
Q4 2014 Compugen Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -22.62% -89.71%
Operating margin -17.02% -99.76%
EBITD margin - -99.76%
Return on average assets -5.18% -12.93%
Return on average equity -5.60% -16.09%
Employees 57 -
CDP Score - -

Address

72 Pinchas Rosen St.
TEL AVIV-YAFO, 69512
Israel
+972-3-7658585 (Phone)
+972-3-7658555 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Compugen Ltd. is a drug discovery and development company. The initial fields of focus selected by the Company are monoclonal antibodies and therapeutic proteins to address unmet needs in the fields of oncology and immunology. Its business primarily involves collaborations covering the further development and commercialization of its discovered product candidates and various forms of research and discovery agreements. The Company´┐Żs pipeline Program consists of therapeutic product candidates at various stages, ranging from validation to pre-clinical studies. Under this Pipeline Program, newly discovered molecules enter the program when they begin experimental evaluation following their in silico prediction and selection. The Pipeline Program consists of in vitro and in vivo experimental validation, including animal disease model or similar testing, followed by various preclinical activities for selected molecules for up to an additional 18 months.

Officers and directors

Martin S. Gerstl Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Anat Cohen-Dayag Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Avihai Shen Interim Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
John Hunter Vice President - Antibody Research & Development
Age: 50
Bio & Compensation  - Reuters
Dov Hershberg Director
Age: 73
Bio & Compensation  - Reuters
Alex Kotzer Director
Age: 66
Bio & Compensation  - Reuters
Yair Aharonowitz Ph.D. Independent External Director
Age: 72
Bio & Compensation  - Reuters
Ruth Arnon Independent Director
Age: 81
Bio & Compensation  - Reuters
Arie Ovadia Ph.D Independent External Director
Age: 65
Bio & Compensation  - Reuters